Dermatologica Sinica (Sep 2017)

An investigator-initiated, open-label, single-center, proof-of-concept-study of omalizumab in patients with poorly controlled acute urticaria

  • Hsien-Yi Chiu

DOI
https://doi.org/10.1016/j.dsi.2017.02.002
Journal volume & issue
Vol. 35, no. 3
pp. 161 – 162

Abstract

Read online

No abstracts available.